---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010112"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:25:39.278510+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dermata: XYNGARI Phase 3 STAR-1 acne trial meets co-primary endpoints; cash $9.7M

## Summary
- XYNGARI Phase 3 STAR-1 achieved statistically significant results on all co-primary endpoints at all time points vs placebo.
- Entered clinical trial collaboration with Revance to study DMT410 with DAXXIFY for axillary hyperhidrosis.
- Raised $8.8M gross proceeds from private placement and warrant inducement financings in Q1 2025.
- Cash and equivalents $9.7M as of March 31, 2025, up from $3.2M; expected to fund operations into Q1 2026.
- R&D expenses $1.3M, G&A $1.1M; operating cash burn $1.9M in Q1 2025.

## SEC filing metadata
- accession: 0001641172-25-010112
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000164117225010112/0001641172-25-010112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000164117225010112/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010112
- JSON: https://secwatch.observer/filing/0001641172-25-010112.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.